JPTXF yields 1.29% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, JPTXF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JPTXF + JNJ for your $10,000?
Japan Petroleum Exploration Co., Ltd., together with its subsidiaries, explores for, develops, produces, and sells oil, natural gas, and other energy resources in Japan and internationally. The company operates 10 domestic oil and natural gas fields in onshore and offshore of Hokkaido, Akita, Yamagata, and Niigata prefectures. It also owns and manages a natural gas pipeline network with a total length of approximately 800 kilometres. In addition, the company is involved in well drilling and engineering contracting business; manufacturing and selling oil products; real estate management and insurance agency activities; sale and contracted transportation of crude oil; recycling of waste oil; and pipeline management and maintenance operations. Further, it engages in the geophysical exploration work contracting and geophysical exploration technology development; geophysical logging and mud logging work contract; exploration, development, and production of tight oil, oil sands, and shale gas; purchase and sale of LNG, petroleum products, etc.; provision of industrial disaster prevention and security services; development of solar, wind, geothermal, biomass, and other renewable energy sources; supply of electric power; manufacture and sale of drilling mud preparations and mud; and operation and commissioning of natural power plants. The company was founded in 1955 and is headquartered in Tokyo, Japan.
Full JPTXF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.